MX2019002926A - Agentes de enlace selectivos antagonistas de la proteina de enlace de osteoprotegerina. - Google Patents
Agentes de enlace selectivos antagonistas de la proteina de enlace de osteoprotegerina.Info
- Publication number
- MX2019002926A MX2019002926A MX2019002926A MX2019002926A MX2019002926A MX 2019002926 A MX2019002926 A MX 2019002926A MX 2019002926 A MX2019002926 A MX 2019002926A MX 2019002926 A MX2019002926 A MX 2019002926A MX 2019002926 A MX2019002926 A MX 2019002926A
- Authority
- MX
- Mexico
- Prior art keywords
- osteoprotegerin
- binding protein
- binding agents
- agents
- opgbp
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se proporcionan por la invención, agentes de enlace selectivos de la proteína de enlace de la osteoprotegerina (OPGbp). Más particularmente, la invención proporciona anticuerpos y dominios de enlace de antígenos que se enlazan selectivamente a una OPGbp, y se pueden usar para prevenir o tratar condiciones relacionadas con la pérdida de masa ósea. Se proporcionan también las moléculas de ácido nucleico que codifican los anticuerpos y los dominios de enlace de antígenos, y los vectores de expresión y las células huésped para la producción de los mismos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51113900A | 2000-02-23 | 2000-02-23 | |
US09/791,153 US20030103978A1 (en) | 2000-02-23 | 2001-02-22 | Selective binding agents of osteoprotegerin binding protein |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019002926A true MX2019002926A (es) | 2019-07-18 |
Family
ID=24033610
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013014759A MX363225B (es) | 2000-02-23 | 2001-02-23 | Agentes de enlace selectivos antagonistas de la proteina de enlace de osteoprotegerina. |
MX2019002926A MX2019002926A (es) | 2000-02-23 | 2002-08-21 | Agentes de enlace selectivos antagonistas de la proteina de enlace de osteoprotegerina. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013014759A MX363225B (es) | 2000-02-23 | 2001-02-23 | Agentes de enlace selectivos antagonistas de la proteina de enlace de osteoprotegerina. |
Country Status (13)
Country | Link |
---|---|
US (2) | US20030103978A1 (es) |
EP (5) | EP2330197B1 (es) |
JP (7) | JP5279425B2 (es) |
AT (1) | ATE398676T2 (es) |
CY (5) | CY1108297T1 (es) |
DK (4) | DK1257648T4 (es) |
ES (5) | ES2505144T3 (es) |
HK (1) | HK1158696A1 (es) |
LT (1) | LT2105449T (es) |
MX (2) | MX363225B (es) |
PT (5) | PT2330197E (es) |
SI (3) | SI2330197T1 (es) |
TW (1) | TWI322182B (es) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL117175A (en) * | 1995-02-20 | 2005-11-20 | Sankyo Co | Osteoclastogenesis inhibitory factor protein |
DK0951551T4 (da) | 1996-12-23 | 2012-09-10 | Immunex Corp | Ligand for NF-kappa B-receptoraktivator, ligand er medlem af TNF-superfamilien |
HU229841B1 (en) * | 1997-04-15 | 2014-09-29 | Daiichi Sankyo Co Ltd | Antibodies against obm |
US6316408B1 (en) * | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
EP1717315A3 (en) * | 1997-04-16 | 2007-06-20 | Amgen Inc. | Osteoprotegerin binding proteins and receptors |
CA2328140C (en) | 1998-05-14 | 2012-03-13 | Immunex Corporation | Method of inhibiting osteoclast activity |
CA2481074A1 (en) * | 2002-04-05 | 2003-10-23 | Amgen Inc. | Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors |
US7052694B2 (en) * | 2002-07-16 | 2006-05-30 | Mayo Foundation For Medical Education And Research | Dendritic cell potentiation |
CA2523912A1 (en) * | 2003-04-30 | 2004-11-11 | Japan Science And Technology Agency | Human antihuman interleukin-18 antibody, fragment thereof and method of using the same |
US20060099203A1 (en) * | 2004-11-05 | 2006-05-11 | Pease Larry R | B7-DC binding antibody |
WO2006017759A2 (en) * | 2004-08-05 | 2006-02-16 | Kirin Brewery Co., Ltd. | Tumor endothelial marker-1 (tem1) binding antibodies and uses thereof |
PE20070684A1 (es) * | 2005-11-14 | 2007-08-06 | Amgen Inc | MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP |
US20080107597A1 (en) * | 2006-01-12 | 2008-05-08 | Anaptys Biosciences, Inc. | Isolation of antibodies that cross-react and neutralize rankl originating from multiple species |
KR20100115360A (ko) | 2008-02-05 | 2010-10-27 | 브리스톨-마이어스 스큅 컴퍼니 | 알파 5-베타 1 항체 및 이의 용도 |
KR20110043786A (ko) * | 2008-08-20 | 2011-04-27 | 센토코 오르토 바이오테크 인코포레이티드 | 조작된 항-il-13 항체, 조성물, 방법 및 용도 |
KR101151805B1 (ko) | 2008-10-20 | 2012-06-01 | 광주과학기술원 | 바이포달 펩타이드 바인더 |
JP5677454B2 (ja) * | 2009-12-11 | 2015-02-25 | グワンジュ・インスティテュート・オブ・サイエンス・アンド・テクノロジー | 細胞内ターゲット結合用二座ペプチドバインダー |
CN103533951B (zh) | 2011-04-08 | 2017-04-19 | 安姆根有限公司 | 使用生长分化因子15(gdf‑15)治疗或改善代谢障碍的方法 |
EP3683228A3 (en) | 2012-01-26 | 2020-07-29 | Amgen Inc. | Growth differentiation factor 15 (gdf-15) polypeptides |
UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
US9753030B2 (en) * | 2013-03-06 | 2017-09-05 | University of Pittsburgh—of the Commonwealth System of Higher Education | Degradable carbon nanotube-containing biosensors and methods for target clinical marker detection |
WO2014144817A2 (en) | 2013-03-15 | 2014-09-18 | Amgen Inc. | Inhibitory polypeptides specific to wnt inhibitors |
MA38873B1 (fr) | 2013-07-31 | 2018-11-30 | Amgen Inc | Constructions contenant le facteur 15 de différentiation de croissance (gdf-15) |
WO2015035215A1 (en) | 2013-09-05 | 2015-03-12 | Amgen Inc. | Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles |
EP3143404B1 (en) | 2014-05-16 | 2018-08-29 | Amgen Inc. | Assay for detecting th1 and th2 cell populations |
GB201419094D0 (en) | 2014-10-27 | 2014-12-10 | Agency Science Tech & Res | Anti-TIM-3-antibodies |
KR20170075778A (ko) | 2014-10-27 | 2017-07-03 | 에이전시 포 사이언스, 테크놀로지 앤드 리서치 | 항-tim-3 항체 |
KR20180030917A (ko) * | 2015-08-05 | 2018-03-26 | 얀센 바이오테크 인코포레이티드 | 항-cd154 항체 및 그의 사용 방법 |
CN110418846A (zh) | 2017-03-14 | 2019-11-05 | 美国安进公司 | 细胞培养物中产生的抗体的总去岩藻糖基化糖型的控制 |
KR20200135781A (ko) | 2018-03-26 | 2020-12-03 | 암젠 인크 | 세포 배양에서 생산된 항체의 총 비푸코실화 당형태 |
CA3096097A1 (en) | 2018-04-09 | 2019-10-17 | Amgen Inc. | Growth differentiation factor 15 fusion proteins |
CA3152547A1 (en) | 2019-09-26 | 2021-04-01 | Amgen Inc. | Methods of producing antibody compositions |
US20230273126A1 (en) | 2020-06-04 | 2023-08-31 | Amgen Inc. | Assessment of cleaning procedures of a biotherapeutic manufacturing process |
US20230416343A1 (en) * | 2020-08-07 | 2023-12-28 | Sorrento Therapeutics, Inc. | Neutralizing Antibodies that Bind the SARS-COV-2 S Protein |
JP2023548767A (ja) | 2020-10-15 | 2023-11-21 | アムジエン・インコーポレーテツド | 抗体製造方法における相対不対グリカン |
AR126089A1 (es) | 2021-06-07 | 2023-09-13 | Amgen Inc | Uso de fucosidasa para controlar el nivel de afucosilación de proteínas glucosiladas |
MX2024003852A (es) | 2021-10-05 | 2024-05-24 | Amgen Inc | Unión al receptor fc-gamma y contenido de glucanos. |
WO2023215725A1 (en) | 2022-05-02 | 2023-11-09 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) * | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
US4474893A (en) * | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4615885A (en) | 1983-11-01 | 1986-10-07 | Terumo Kabushiki Kaisha | Pharmaceutical composition containing urokinase |
EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
US4699880A (en) * | 1984-09-25 | 1987-10-13 | Immunomedics, Inc. | Method of producing monoclonal anti-idiotype antibody |
US4959314A (en) * | 1984-11-09 | 1990-09-25 | Cetus Corporation | Cysteine-depleted muteins of biologically active proteins |
US6150090A (en) * | 1986-01-09 | 2000-11-21 | Massachusetts Institute Of Technology | Nuclear factors associated with transcriptional regulation |
US5106627A (en) * | 1987-11-17 | 1992-04-21 | Brown University Research Foundation | Neurological therapy devices |
US4892538A (en) * | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
US5158881A (en) | 1987-11-17 | 1992-10-27 | Brown University Research Foundation | Method and system for encapsulating cells in a tubular extrudate in separate cell compartments |
US5846534A (en) * | 1988-02-12 | 1998-12-08 | British Technology Group Limited | Antibodies to the antigen campath-1 |
HU222810B1 (hu) | 1988-05-27 | 2003-11-28 | Synergen Inc. | Interleukin-1 inhibitorok, ezeket kódoló DNS-szekvenciák, a szekvenciákat tartalmazó rekombináns DNS-vektorok, a vektort tartalmazó gazdasejtek és rekombináns GT-10-il-1i-2A DNS molekula |
US5011472A (en) * | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
DE68925966T2 (de) | 1988-12-22 | 1996-08-29 | Kirin Amgen Inc | Chemisch modifizierte granulocytenkolonie erregender faktor |
AU648505B2 (en) | 1989-05-19 | 1994-04-28 | Amgen, Inc. | Metalloproteinase inhibitor |
CA2071912C (en) * | 1990-11-30 | 2002-10-15 | Hanne Bentz | Use of a bone morphogenetic protein in synergistic combination with tgf-beta for bone repair |
US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
US5118667A (en) * | 1991-05-03 | 1992-06-02 | Celtrix Pharmaceuticals, Inc. | Bone growth factors and inhibitors of bone resorption for promoting bone formation |
MX9204303A (es) * | 1991-07-23 | 1993-11-01 | Rhone Poulenc Rorer Int | Factor regulador del crecimiento de osteoclasto. |
US5961974A (en) * | 1991-10-25 | 1999-10-05 | Immunex Corporation | Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same |
WO1993015722A1 (en) | 1992-02-07 | 1993-08-19 | Syntex (Usa) Inc. | Controlled delivery of pharmaceuticals from preformed porous microparticles |
US5234784A (en) * | 1992-04-01 | 1993-08-10 | Eastman Kodak Company | Method of making a projection viewable transparency comprising an electrostatographic toner image |
US5578569A (en) * | 1993-03-12 | 1996-11-26 | Tam; Cherk S. | Method of increasing bone growth |
US5457035A (en) * | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
DE69427588T2 (de) * | 1993-09-14 | 2002-04-25 | Merck & Co., Inc. | HUMANE PROTEIN-TYROSINPHOSPHATASE DECODIERENDE cDNA |
US5641747A (en) * | 1994-07-25 | 1997-06-24 | Temple University-Of The Commonwealth System Of Higher Education | Treatment of osteopetrotic diseases |
US20030166097A1 (en) * | 1995-03-15 | 2003-09-04 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor |
US7094564B1 (en) * | 1995-03-15 | 2006-08-22 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor |
US5843901A (en) | 1995-06-07 | 1998-12-01 | Advanced Research & Technology Institute | LHRH antagonist peptides |
DK1666591T3 (da) * | 1995-06-29 | 2011-05-23 | Immunex Corp | Cytokin der inducerer apoptose |
US6613544B1 (en) * | 1995-12-22 | 2003-09-02 | Amgen Inc. | Osteoprotegerin |
US6369027B1 (en) | 1995-12-22 | 2002-04-09 | Amgen Inc. | Osteoprotegerin |
US6046048A (en) * | 1996-01-09 | 2000-04-04 | Genetech, Inc. | Apo-2 ligand |
US5981220A (en) * | 1996-03-27 | 1999-11-09 | Human Genome Sciences, Inc. | Epidermal differentiation factor |
TW555765B (en) | 1996-07-09 | 2003-10-01 | Amgen Inc | Low molecular weight soluble tumor necrosis factor type-I and type-II proteins |
EP0948530A2 (en) * | 1996-12-13 | 1999-10-13 | Schering Corporation | Mammalian cell surface antigens; related reagents |
EP0951546A2 (en) * | 1996-12-20 | 1999-10-27 | The Board Of Regents, The University Of Texas System | Compositions and methods of use for osteoclast inhibitory factors |
US6271349B1 (en) * | 1996-12-23 | 2001-08-07 | Immunex Corporation | Receptor activator of NF-κB |
DK0951551T4 (da) * | 1996-12-23 | 2012-09-10 | Immunex Corp | Ligand for NF-kappa B-receptoraktivator, ligand er medlem af TNF-superfamilien |
HU229841B1 (en) * | 1997-04-15 | 2014-09-29 | Daiichi Sankyo Co Ltd | Antibodies against obm |
CA2286290A1 (en) | 1997-04-15 | 1998-10-22 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
US5843678A (en) * | 1997-04-16 | 1998-12-01 | Amgen Inc. | Osteoprotegerin binding proteins |
EP1717315A3 (en) * | 1997-04-16 | 2007-06-20 | Amgen Inc. | Osteoprotegerin binding proteins and receptors |
US6316408B1 (en) * | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
AU7705098A (en) * | 1997-05-29 | 1998-12-30 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor-like protein 8 |
US6087555A (en) * | 1997-10-15 | 2000-07-11 | Amgen Inc. | Mice lacking expression of osteoprotegerin |
US7063960B2 (en) * | 1997-12-12 | 2006-06-20 | The Rockefeller University | Protein belonging to the TNF superfamily involved in signal transduction, nucleic acids encoding same, and methods of use thereof |
CA2328140C (en) * | 1998-05-14 | 2012-03-13 | Immunex Corporation | Method of inhibiting osteoclast activity |
EP1114166B1 (en) * | 1998-09-15 | 2005-03-23 | Pharmexa A/S | Method for down-regulating osteoprotegerin ligand activity |
DE60129254T2 (de) * | 2000-09-22 | 2008-03-13 | Immunex Corp., Thousand Oaks | Screeningverfahren für agonisten und antagonisten des rezeptoraktivators von nf-kappa b |
MXPA03010531A (es) * | 2001-05-17 | 2004-07-01 | Immunex Corp | Uso terapeutico de antagonistas de rank. |
US20030021785A1 (en) * | 2001-06-06 | 2003-01-30 | Dougall William C. | Use of rank antagonists to treat cancer |
RS54274B1 (en) * | 2001-06-26 | 2016-02-29 | Amgen Fremont Inc. | ANGELS FOR OPGL |
US7084257B2 (en) * | 2001-10-05 | 2006-08-01 | Amgen Inc. | Fully human antibody Fab fragments with human interferon-gamma neutralizing activity |
CA2481074A1 (en) * | 2002-04-05 | 2003-10-23 | Amgen Inc. | Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors |
US9300829B2 (en) | 2014-04-04 | 2016-03-29 | Canon Kabushiki Kaisha | Image reading apparatus and correction method thereof |
-
2001
- 2001-02-22 US US09/791,153 patent/US20030103978A1/en not_active Abandoned
- 2001-02-23 EP EP10010586.5A patent/EP2330197B1/en not_active Expired - Lifetime
- 2001-02-23 EP EP10013041.8A patent/EP2305715B1/en not_active Expired - Lifetime
- 2001-02-23 EP EP08010991.1A patent/EP2105449B1/en not_active Expired - Lifetime
- 2001-02-23 DK DK01911158.2T patent/DK1257648T4/en active
- 2001-02-23 TW TW090104205A patent/TWI322182B/zh not_active IP Right Cessation
- 2001-02-23 DK DK10013041.8T patent/DK2305715T3/en active
- 2001-02-23 PT PT100105865T patent/PT2330197E/pt unknown
- 2001-02-23 MX MX2013014759A patent/MX363225B/es unknown
- 2001-02-23 DK DK10010586.5T patent/DK2330197T3/en active
- 2001-02-23 EP EP16198812.6A patent/EP3184545B1/en not_active Expired - Lifetime
- 2001-02-23 ES ES10010586.5T patent/ES2505144T3/es not_active Expired - Lifetime
- 2001-02-23 LT LTEP08010991.1T patent/LT2105449T/lt unknown
- 2001-02-23 ES ES16198812T patent/ES2758881T3/es not_active Expired - Lifetime
- 2001-02-23 ES ES10013041.8T patent/ES2612124T3/es not_active Expired - Lifetime
- 2001-02-23 PT PT80109911T patent/PT2105449T/pt unknown
- 2001-02-23 SI SI200131038T patent/SI2330197T1/sl unknown
- 2001-02-23 AT AT01911158T patent/ATE398676T2/de active
- 2001-02-23 PT PT100130418T patent/PT2305715T/pt unknown
- 2001-02-23 SI SI200131071T patent/SI2105449T1/sl unknown
- 2001-02-23 PT PT161988126T patent/PT3184545T/pt unknown
- 2001-02-23 EP EP19203092.2A patent/EP3613775A1/en not_active Ceased
- 2001-02-23 ES ES08010991T patent/ES2738798T3/es not_active Expired - Lifetime
- 2001-02-23 SI SI200130847T patent/SI1257648T1/sl unknown
- 2001-02-23 DK DK16198812.6T patent/DK3184545T3/da active
- 2001-02-23 ES ES01911158.2T patent/ES2307594T5/es not_active Expired - Lifetime
- 2001-02-23 PT PT01911158T patent/PT1257648E/pt unknown
-
2002
- 2002-08-21 MX MX2019002926A patent/MX2019002926A/es unknown
-
2008
- 2008-08-26 CY CY20081100919T patent/CY1108297T1/el unknown
- 2008-09-17 JP JP2008237535A patent/JP5279425B2/ja not_active Expired - Lifetime
-
2011
- 2011-12-08 HK HK11113289.0A patent/HK1158696A1/xx not_active IP Right Cessation
-
2013
- 2013-01-10 JP JP2013002331A patent/JP5747048B2/ja not_active Expired - Lifetime
- 2013-03-14 US US13/830,441 patent/US20140147444A1/en not_active Abandoned
-
2014
- 2014-10-10 CY CY20141100821T patent/CY1115634T1/el unknown
- 2014-12-09 JP JP2014248643A patent/JP5981981B2/ja not_active Expired - Lifetime
-
2016
- 2016-05-31 JP JP2016109167A patent/JP6453810B2/ja not_active Expired - Lifetime
-
2017
- 2017-01-11 CY CY20171100035T patent/CY1118462T1/el unknown
- 2017-10-17 JP JP2017200890A patent/JP6647730B2/ja not_active Expired - Lifetime
-
2018
- 2018-08-24 JP JP2018156987A patent/JP2019022486A/ja active Pending
-
2019
- 2019-08-26 CY CY20191100907T patent/CY1121931T1/el unknown
- 2019-12-17 CY CY20191101324T patent/CY1122686T1/el unknown
- 2019-12-24 JP JP2019232697A patent/JP2020062034A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1158696A1 (en) | Antagonistic selective binding agents of osteoprotegerin binding protein | |
JOP20190017A1 (ar) | أجسام مضادة ترتبط مع مستقبل cgrp بشري | |
MXPA02012743A (es) | Moleculas tipo il-17 y usos de las mismas. | |
YU9403A (sh) | Anti-dualna antitela integrina, kompozicije, postupci i primene | |
WO2002020569A3 (en) | Mammalian genes; related reagents and methods | |
MX348154B (es) | Anticuerpos de enlace a il-1-beta y fragmentos de los mismos. | |
WO2001049728A3 (en) | HUMAN PROTEINS HAVING HYDROPHOBIC DOMAINS AND DNAs ENCODING THESE PROTEINS | |
WO2005058815A3 (en) | Ip-10 antibodies and their uses | |
WO2001068859A3 (en) | Il-17 receptor like molecules and uses thereof | |
WO2001068705A3 (en) | Il-17 receptor like molecules and uses thereof | |
AU8881201A (en) | Tnf receptor-like molecules and uses thereof | |
EP1517144A3 (en) | Method of identifying an antibody binding to and modulating the activity of a human vanilloid receptor | |
TW200508246A (en) | Anti-dengue virus antibodies, compositions, methods and uses | |
WO2001025432A3 (en) | Histamine receptor | |
WO2003057821A3 (en) | Mut-il-18 or mut-il-18r proteins, antibodies, compositions, methods and uses | |
PL374550A1 (en) | Il-17 like molecules and uses thereof | |
WO2001066752A3 (en) | Reproduction-specific genes | |
WO2001074903A3 (en) | Cd20/ige-receptor like molecules and uses thereof | |
NZ512332A (en) | Potassium channel interactors and uses therefor | |
WO2003046125A3 (en) | Hin-2 nucleic acid molecules, proteins, antibodies, homologues, receptors, and uses thereof | |
WO2001051642A3 (en) | Dna modification proteins | |
WO2002038795A3 (en) | Braf35 protein and brca2/braf35 complex and methods of use | |
EP1482038A4 (en) | NOVEL PROTEIN AND DNA THEREOF | |
MY155265A (en) | Anti-dual integrin antibodies, compositions, methods and uses |